Indianapolis, IN, United States of America

Tony Yantao Zhang

This inventor holds 23 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Eli Lilly and Company, Reilly Industries, Inc., Avera Pharmaceuticals, Inc.. Active years: 1993-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tony Yantao Zhang. Retrieved from https://idiyas.com/inventor/tony-yantao-zhang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 23 

% Patents Active = 78.3


 

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 60(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1993 - 2007)
  • Fishers, IN (US) (2022 - 2024)

Company Filing History:


Years Active: 1993-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
TRK Inhibitors
Pharmaceutical Compositions
Arylpiperazines
Synthesis Processes
Benzothiophenes
Vinyl Sulfoxides
Hydrazones
Pyridine Derivatives
Dihydrothiadiazoles
Triazinones
23 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tony Yantao Zhang

Tony Yantao Zhang is a prominent inventor based in Indianapolis, IN, with a noteworthy portfolio that includes 22 patents. His innovative work primarily focuses on pharmaceutical advancements and treatments for various diseases, showcasing his dedication to improving healthcare outcomes.

Introduction

With a rich background in pharmaceutical research, Tony Yantao Zhang has made significant strides in the field of biomedicine. His drive to develop effective treatments has led to groundbreaking inventions that continue to make an impact in the industry.

Latest Patents

Among his latest patents, Zhang has developed a series of TRK inhibitors that hold promise as anticancer drugs. These compounds, which include an amido-phenoxy-indazole structure fragment, demonstrate potent inhibitory effects on various oncogenic kinases, particularly TRK, making them a valuable option for cancer treatment. Additionally, he has patented a formulation for solid oral fixed dose compositions combining metformin, atorvastatin, and valsartan, along with their pharmaceutically acceptable salts. This invention involves innovative processes for preparation and application in treating certain diseases.

Career Highlights

Throughout his career, Tony has worked for renowned organizations like Eli Lilly and Company and Reilly Industries, Inc. His experiences in these leading pharmaceutical companies have equipped him with the expertise necessary to contribute to significant advancements in the industry.

Collaborations

Tony has collaborated with talented individuals, including James A. Aikins and Eric F. Scriven, demonstrating the value of teamwork in generating innovative solutions. These partnerships have allowed him to combine knowledge and skills, which is essential in the fast-evolving field of pharmaceutical research.

Conclusion

Tony Yantao Zhang’s contributions to the development of new pharmaceutical agents are exceptionally noteworthy. His patents not only highlight his inventive prowess but also underscore his commitment to enhancing cancer treatments and advancing healthcare. As he continues to innovate, the potential for his inventions to make a meaningful impact in the medical field remains promising.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…